Table 2 Univariate analysis of variables associated with overall survival in patients undergoing repeat TACE, with baseline variables (a) and subsequent to initial TACE (b)

Single Tumour

0.76

0.59

1.00

0.043

Albumin, g/L

0.96

0.94

0.98

<0.001

Bilirubin, μmol/L

1.02

1.01

1.03

<0.001

Ascites

1.94

1.35

2.78

<0.001

Hepatic Encephalopathy

1.70

0.99

2.90

0.048

BCLC stage A

0.75

0.58

0.97

0.026

BCLC stage B

1.36

1.04

1.77

0.020

Child Pugh Score (5/6/7/8/9)

1.25

1.13

1.39

<0.001

AFP ≥ 200 ng/ml

1.48

1.07

2.04

0.015

 AFP ≥ 200 ng/ml

2.19

1.43

3.36

<0.001

 Albumin, g/L

0.95

0.93

0.98

<0.001

 Bilirubin, μmol/L

1.02

1.01

1.03

<0.001

 Na, mmol/L

0.95

0.91

0.99

0.010

 INR

1.70

1.12

2.59

0.012

 MELD score

1.07

1.02

1.11

0.004

 Child Pugh Score (5/6/7/8/9)

1.29

1.16

1.43

<0.001

 Ascites

1.66

1.17

2.35

0.004

 Decompensation

3.39

1.85

6.21

<0.001

 Renal dysfunction

3.46

1.07

11.19

0.035

Combination therapy

0.65

0.46

0.91

0.011

 Ablation

0.56

0.35

0.88

0.011

 Resection

0.27

0.10

0.76

0.011